oncolyt
herp
simplex
virus
hsv
undergon
extens
laboratori
investig
kirn
et
al
earli
clinic
trial
aghi
martuza
anticanc
agent
oncolyt
hsv
undergon
clinic
trial
mutat
hsv
gene
andor
encod
viral
ribonucleotid
reductas
vrr
function
allow
replic
wildtyp
hsv
occur
even
quiescent
cell
neuron
infect
enceph
caus
wildtyp
hsv
type
goldstein
weller
without
function
hsv
replic
sever
curtail
quiescent
cell
goldstein
weller
howev
cycl
cell
upregul
express
sphase
specif
gene
mrr
nucleic
acid
metabol
complement
defect
viral
function
thu
allow
mutant
hsv
replic
goldstein
weller
complement
provid
biolog
rational
employ
hsv
oncolyt
therapi
rational
base
preferenti
replic
cycl
versu
quiescent
cell
howev
oncolyt
hsv
target
glioma
cell
replic
moment
time
hoshino
et
al
major
glioma
cell
evad
oncolyt
hsv
therapi
particularli
oncolyt
hsv
administ
intratumor
rare
sphase
specif
treatment
like
radiat
chemotherapi
administ
daili
extend
period
time
allow
target
cell
might
enter
cell
cycl
later
cours
treatment
know
downstream
effect
hereaft
term
tumor
suppressor
gene
human
chromosom
delet
glioblastoma
kamiryo
et
al
prevent
transcript
factor
transcrib
sphase
gene
mrr
elledg
et
al
hypothes
mutat
would
complement
hsv
replic
even
cell
quiescenc
activ
cycl
therebi
enabl
hsv
overcom
limit
infect
quiescent
cell
molecularli
target
fashion
yield
infecti
determin
cultur
human
glioma
fibroblast
cell
cycl
well
quiescent
popul
cell
type
isol
fluoresc
activ
cell
sort
fac
overal
cell
produc
significantli
fibroblast
regardless
cell
cycl
statu
interestingli
ratio
yield
cycl
versu
noncycl
cell
nearli
threefold
higher
normal
fibroblast
glioma
cell
figur
suggest
cellular
machineri
quiescent
glioma
cell
complement
replic
higher
degre
quiescent
fibroblast
glioma
cell
possess
mutat
wang
et
al
investig
role
two
mutat
viral
replic
cultur
cell
experi
repeat
cycl
glioma
cell
express
wildtyp
possess
homozyg
delet
wang
et
al
ratio
yield
glioma
cell
nearli
ident
glioma
cell
figur
find
suggest
mutat
necessari
support
replic
arrest
tumor
cell
agreement
previou
find
cycl
tumor
cell
yoon
et
al
hand
experi
repeat
glioma
cell
komata
et
al
ratio
yield
cell
higher
human
fibroblast
higher
glioma
cell
figur
find
rais
possibl
mutat
might
contribut
support
replic
seen
quiescent
glioma
cell
glioma
tumor
cell
possess
mutat
also
varieti
genet
mutat
could
affect
viral
cellular
replic
farassati
et
al
smith
et
al
yield
determin
cycl
facsisol
murin
embryon
fibroblast
mef
fetal
astrocyt
wildtyp
well
transgen
mice
homozyg
delet
mef
fetal
astrocyt
support
replic
even
wherea
viral
replic
maintain
wildtyp
mef
fetal
astrocyt
figur
compar
result
obtain
pharmacolog
agent
lovastatin
use
induc
growth
arrest
data
shown
find
indic
delet
support
product
replic
hsv
quiescent
cell
confirm
loss
function
would
result
higher
level
mammalian
ribonucleotid
reductas
mrr
gene
express
regardless
cell
cycl
statu
elledg
et
al
measur
mrna
level
subunit
mrr
cycl
rel
noncycl
cell
use
realtim
revers
transcript
rt
cell
mef
ratio
mrr
subunit
mrna
cycl
rel
noncycl
cell
howev
cell
wildtyp
mef
human
fibroblast
mef
ratio
much
higher
figur
find
decreas
mrr
express
noncycl
cell
agre
publish
data
show
mrr
express
cycl
cell
expect
downregul
growtharrest
cell
elledg
et
al
howev
cell
mrr
express
maintain
regardless
cellcycl
statu
agreement
mechan
suppress
mrr
transcript
elledg
et
al
stabli
transfect
glioma
cell
overexpress
subunit
mrr
creat
cell
line
express
mrr
subunit
mrna
data
shown
infect
ratio
viral
yield
cycl
rel
noncycl
compar
seen
cell
nearli
threefold
lower
cell
figur
suggest
stabli
elev
mrr
subunit
express
throughout
cell
cycl
cell
figur
enabl
support
viral
replic
independ
cell
cycl
statu
manner
compar
seen
cell
figur
determin
effect
delet
replic
cell
vivo
studi
replic
toxic
ko
wildtyp
deriv
intracerebr
inocul
wildtyp
knockout
mice
cerebr
viral
titer
similar
wildtyp
hsv
inocul
brain
wildtyp
mice
howev
mice
produc
three
order
magnitud
wildtyp
mice
intracerebr
inocul
figur
viral
dose
kill
inocul
mice
day
inocul
two
order
magnitud
less
inocul
brain
mice
compar
wildtyp
mice
significantli
differ
wildtyp
hsv
inocul
brain
wildtyp
mice
figur
final
anatom
distribut
gene
express
neuron
much
greater
brain
mice
brain
wildtyp
mice
former
also
exhibit
evid
increas
inflammatori
necrot
effect
caus
host
immun
respons
like
aros
due
signific
viral
replic
treatment
group
figur
taken
togeth
find
confirm
valid
hypothesi
retain
signific
replic
abil
cell
defect
even
cell
postmitot
growth
arrest
oncolyt
virus
engin
hsv
produc
signific
anticanc
effect
preclin
model
shown
definit
efficaci
clinic
trial
aghi
martuza
specul
reason
lack
efficaci
includ
viral
dose
less
maximum
toler
dose
mutat
render
oncolyt
hsv
less
potent
ineffici
spatial
tempor
distribut
viru
wein
et
al
antihsv
immun
imped
viral
replic
ikeda
et
al
anoth
reason
limit
efficaci
assum
oncolyt
hsv
infect
lyse
cell
tumor
activ
divid
quiescent
tumor
cell
may
support
viral
replic
case
glioma
tumor
cell
may
activ
cycl
one
time
hoshino
et
al
quiescent
tumor
cell
support
oncolyt
hsv
replic
oncolyt
hsv
would
unabl
treat
tumor
like
glioma
larg
noncycl
fraction
particularli
oncolyt
virus
administ
intratumor
surgeri
unlik
sphase
specif
adjuv
treatment
chemotherapi
radiat
administ
daili
enabl
target
cell
enter
cell
cycl
differ
point
time
howev
result
indic
noncycl
cell
still
support
replic
hsv
find
impli
oncolyt
hsv
repres
molecularli
target
therapi
tumor
defect
tumor
suppressor
pathway
also
impli
type
herp
virus
poxvirus
vaccinia
viru
mccart
et
al
genet
defect
vrr
viral
thymidin
kinas
whose
cellular
ortholog
mammalian
thymidin
kinas
also
transcript
control
tumor
suppressor
pathway
may
also
replic
quiescent
cell
defect
pathway
anoth
type
target
downstream
effector
repres
adenovirus
jiang
et
al
addit
virus
coronaviru
wurding
et
al
measl
viru
nakamura
et
al
engin
select
taken
cell
express
cell
surfac
receptor
mutant
epiderm
growth
factor
receptor
specif
found
tumor
virus
target
cell
alter
ra
mitogen
pathway
exampl
virus
includ
reoviru
norman
et
al
delet
viral
gene
fu
et
al
delet
viral
gene
smith
et
al
virus
target
tumor
cell
propens
exhibit
alter
biochem
properti
vesicular
stomat
viru
target
cell
alter
interferon
respons
stojdl
et
al
adenoviru
target
cell
shut
cellular
protein
synthesi
infect
oshea
et
al
one
key
distinct
type
target
found
hsv
lack
target
virus
target
hsv
lack
allow
infect
quiescent
tumor
cell
carri
delet
repres
cell
glioma
given
moment
time
hoshino
et
al
experiment
approach
compar
mef
mice
mef
wildtyp
mice
valid
hypothesi
hsv
target
nonrepl
cell
delet
superior
approach
employ
tumor
cell
without
appar
intact
gene
loci
tumor
cell
possess
mani
genet
mutat
may
also
affect
viral
replic
farassati
et
al
smith
et
al
even
tumor
cell
appear
intact
gene
loci
may
gene
inactiv
promot
methyl
andor
inactiv
compon
tumor
suppressor
pathway
costello
et
al
ono
et
al
ueki
et
al
burn
et
al
nakamura
et
al
watanab
et
al
ohgaki
kleihu
clinic
trial
continu
carri
oncolyt
virus
import
determin
retrospect
prospect
enhanc
viral
replic
patient
whose
tumor
carri
particular
mutat
known
complement
viral
defect
trial
determin
statu
tumor
suppressor
pathway
treat
tumor
may
crucial
order
identifi
patient
tumor
sensit
agent
